… of the current COVID-19 pandemic, and the lack of therapies of proven efficacy should in
no way legitimize a failure of the scientific method. The validity of a given therapy must be …

… We therefore advocate that therapeutic guidelines retain lopinavir–ritonavir as a treatment
option against Covid-19, pending completion of the World Health Organization SOLIDARITY …

… is of the ability to inhibit SARS-CoV-2 protease, ritonavir alone … of ritonavir and lopinavir in
COVID-19 treatment, lopinavir … study of COVID-19, the combination of lopinavir-ritonavir and …

… drug reactions of nirmatrelvir/ritonavir can be expected in COVID-19 patients, as have
been … of oral nirmatrelvir/ritonavir therapy may effectively decrease the risk of COVID-19-related …

… , is more beneficial compared with standard of care or adjuvant therapies alone in regards
… patients with COVID-19. We also examined the safety of LPV/r therapy in COVID-19 patients, …

… A combination of favipiravir with other supportive therapy showed more favorable outcomes
for COVID-19 patients. Furthermore, the use of lopinavir/ritonavir in COVID-19 patients …

… therapeutic scheme against COVID-19. The study aimed to investigate whether lopinavir/ritonavir
(… pneumonia-associated adjuvant drugs has a better therapeutic effect on COVID-19. …

… This study shows the positive effects of LPV/r therapy. Two reviews, including a Chinese
review and communication showed that LPV may be drug treatment option for COVID-19. …

… Thus far, there are no specific therapeutic agents for coronavirus infections. After the
emergence of severe acute respiratory syndrome (SARS) in 2003, screening of approved drugs …

… A systematic review of lopinavir-ritonavir therapy in patients of … for the use of lopinavir-ritonavir
in the treatment of COVID-19 is now … in COVID-19 patients treated with lopinavir-ritonavir …